Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?

Few data are available on the prevention of fracture in glucocorticoid-treated premenopausal women with autoimmune disorders such as systemic lupus erythematosus. In this setting, Okada et al . compared the effect of coadministration of alfacalcidol alone with that of alfacalcidol combined with alen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature clinical practice. Rheumatology 2009-02, Vol.5 (2), p.74-75
Hauptverfasser:	Lems, William F, Geusens, Piet P
Format:	Artikel
Sprache:	eng
Schlagworte:	Alendronate Bisphosphonates Bone density Bones Corticosteroids Density Dosage and administration Fractures Lupus Medicine Medicine & Public Health Osteoporosis Phosphatase practice-point Prevention Rheumatology Risk factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Few data are available on the prevention of fracture in glucocorticoid-treated premenopausal women with autoimmune disorders such as systemic lupus erythematosus. In this setting, Okada et al . compared the effect of coadministration of alfacalcidol alone with that of alfacalcidol combined with alendronate. After 12 months of treatment, lumbar spine bone mineral density increased by 1.7% in the combination group, but decreased by 9.9% in the alfacalcidol-only group ( P
ISSN:	1745-8382 1759-4790 1745-8390 1759-4804
DOI:	10.1038/ncprheum0991